what is the cost-effectiveness of dry eye syndrome

Introduction

Dry eye syndrome (DES) is a prevalent ocular condition characterized by insufficient tear production or excessive tear evaporation, leading to discomfort, visual disturbances, and potential damage to the ocular surface. The economic burden and cost-effectiveness of various treatments for DES are critical considerations for healthcare providers and policymakers.

Key Insights

Cost-Effectiveness of Topical Cyclosporine:
- Topical cyclosporine 0.05% is cost-effective for moderate to severe DES unresponsive to conventional therapy, with a societal perspective incremental cost-utility ratio (CUR) of $34,953 per quality-adjusted life year (QALY) and an average CUR of $11,199 per QALY.
- The third-party-insurer incremental CUR is $37,179 per QALY, while the average CUR is $34,343 per QALY.
Efficacy and Safety of Topical Cyclosporine:
- Topical cyclosporine 0.05% significantly improves both objective and subjective outcomes in DES patients, including lower Ocular Surface Disease Index scores, longer tear film breakup time, improved Schirmer I scores, reduced corneal fluorescein staining, and higher goblet cell densities.
- However, it is associated with more adverse effects compared to controls.
Cost-Effectiveness of Ophthalmic Lubricants:
- Systane® is more effective than Refresh Tears® at improving symptoms of dryness, with an incremental cost-effectiveness ratio (ICER) of $5,837 per QALY, which is well below the generally accepted $50,000 per QALY threshold.
Economic Burden of DES:
- The average annual cost of managing a patient with DES is $783 from the payer's perspective and $11,302 from a societal perspective, with the overall burden on the US healthcare system estimated at $3.84 billion and $55.4 billion to US society overall.
- Pharmacological treatments, particularly lubricants, account for the majority of the expenditure on DES treatment.

Conclusion

The treatment of dry eye syndrome, particularly with topical cyclosporine and ophthalmic lubricants, is generally cost-effective, providing significant improvements in quality of life for patients. However, the economic burden of DES remains substantial, highlighting the need for efficient management strategies to mitigate costs while ensuring effective patient care.

What is the cost-effectiveness of dry eye syndrome

Summary

Introduction

Key Insights

Conclusion

Sources and full results

Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome.

Topical cyclosporine emulsion, 0.05%, is a cost-effective therapy for moderate to severe dry eye syndrome unresponsive to conventional therapy.

Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis.

Topical 0.05% cyclosporine eye drops significantly improved both objective and subjective outcomes in dry eye syndrome patients, but had more adverse effects.

Efficacy of polyunsaturated fatty acids for dry eye syndrome: a meta-analysis of randomized controlled trials.

Polyunsaturated fatty acids supplementation shows potential as an effective therapy for dry eye syndrome, reducing symptom severity and ocular surface disease index scores.

United States Cost-Effectiveness Study of Two Dry Eye Ophthalmic Lubricants

Both Refresh Tears® and Systane® are effective and cost-effective treatments for dry eye, with Systane® being more effective but costing more per year.

Dry eye syndrome: an update in office management.

Dry eye syndrome can be effectively treated with artificial tears, anti-inflammatory agents, and immunosuppressants, improving the quality of life for individuals and preventing damage to the ocular surface.

A new look at dry eye disease and its treatment

Topical cyclosporine may improve quality of life and reduce healthcare costs in dry eye disease, linking it to T-cell-mediated inflammation.

Cost of Dry Eye Treatment in an Asian Clinic Setting

Dry eye treatment costs significantly more than estimated, with pharmacological treatments accounting for 99.2% of total expenditure, and true societal costs likely to be higher than estimated.

The Economic Burden of Dry Eye Disease in the United States: A Decision Tree Analysis

Dry eye disease (DED) poses a substantial economic burden on the US healthcare system and society, with an average annual cost of $783 per patient and $55.4 billion to society overall.

Dry eye syndrome. Etiological and therapeutic aspects.

Topical A Cyclosporine and androgen drops show potential as a new therapeutic approach for dry eye syndrome, with potential benefits for patients with various underlying conditions.

The management of dry eye

Artificial tears and ocular lubricants are the mainstay of treatment for dry eye disease, with a prevalence ranging from 8-34% and affecting more women than men.

Try another search